Bahman Khameneh1, Bibi Sedigheh Fazly Bazzaz2, Alireza Amani3, Javad Rostami3, Nasser Vahdati-Mashhadian4. 1. Department of Pharmaceutical Control, Students Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Students Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran; Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: vahdatin@mums.ac.ir.
Abstract
BACKGROUNDS: Hepatotoxicity due to anti tuberculosis drugs, rifampin and isoniazid, is a major problem in tuberculosis patients. Vitamin C, an antioxidant, and N-acetyl cysteine (NAC), a scavenger of active metabolites, reduce the hepatotoxicity. The aim of present study was to investigate the effect of vitamin C and NAC individually on the antibacterial activity of anti tuberculosis drugs against Mycobacterium tuberculosis and Staphylococcus aureus strains. METHODS: The MICs of each compound against all strains were determined in 96 wells plate. Rifampin was tested at serial two fold concentrations alone or in combination with NAC or vitamin C. RESULTS: The MIC of rifampin against different strains of S. aureus was 0.008-0.032 μg/ml. The MIC of rifampin and isoniazid against M. tuberculosis strains were 40 and 0.2 μg/ml, respectively. Vitamin C and NAC had no antibacterial activity against all strains. MIC of rifampin was reduced two fold by combination with vitamin C for all S. aureus strains, while NAC did not affect the antibacterial activity of rifampin. Vitamin C and NAC had remarkable effects on the antibacterial activity of anti-tuberculosis drugs against M. tuberculosis. CONCLUSIONS: Synergistic effects were observed between rifampin or isoniazid and vitamin C against all tested strains. However, combination therapy of rifampin and isoniazid with NAC was not being effective. This study highlighted the advantages of combination of anti-tuberculosis drugs and vitamin C to eradicate the microbial infections.
BACKGROUNDS: Hepatotoxicity due to anti tuberculosis drugs, rifampin and isoniazid, is a major problem in tuberculosispatients. Vitamin C, an antioxidant, and N-acetyl cysteine (NAC), a scavenger of active metabolites, reduce the hepatotoxicity. The aim of present study was to investigate the effect of vitamin C and NAC individually on the antibacterial activity of anti tuberculosis drugs against Mycobacterium tuberculosis and Staphylococcus aureus strains. METHODS: The MICs of each compound against all strains were determined in 96 wells plate. Rifampin was tested at serial two fold concentrations alone or in combination with NAC or vitamin C. RESULTS: The MIC of rifampin against different strains of S. aureus was 0.008-0.032 μg/ml. The MIC of rifampin and isoniazid against M. tuberculosis strains were 40 and 0.2 μg/ml, respectively. Vitamin C and NAC had no antibacterial activity against all strains. MIC of rifampin was reduced two fold by combination with vitamin C for all S. aureus strains, while NAC did not affect the antibacterial activity of rifampin. Vitamin C and NAC had remarkable effects on the antibacterial activity of anti-tuberculosis drugs against M. tuberculosis. CONCLUSIONS: Synergistic effects were observed between rifampin or isoniazid and vitamin C against all tested strains. However, combination therapy of rifampin and isoniazid with NAC was not being effective. This study highlighted the advantages of combination of anti-tuberculosis drugs and vitamin C to eradicate the microbial infections.
Authors: Carolina Geadas; Sonia K Stoszek; David Sherman; Bruno B Andrade; Sudha Srinivasan; Carol D Hamilton; Jerrold Ellner Journal: Tuberculosis (Edinb) Date: 2016-11-27 Impact factor: 2.973
Authors: Santosh Pandit; Vaishnavi Ravikumar; Alyaa M Abdel-Haleem; Abderahmane Derouiche; V R S S Mokkapati; Carina Sihlbom; Katsuhiko Mineta; Takashi Gojobori; Xin Gao; Fredrik Westerlund; Ivan Mijakovic Journal: Front Microbiol Date: 2017-12-22 Impact factor: 5.640
Authors: Saga Helgadóttir; Santosh Pandit; Venkata R S S Mokkapati; Fredrik Westerlund; Peter Apell; Ivan Mijakovic Journal: Front Cell Infect Microbiol Date: 2017-02-22 Impact factor: 5.293